Literature DB >> 16248989

Divergent effects of Abeta1-42 on ionotropic glutamate receptor-mediated responses in CA1 neurons in vivo.

Viktor Szegedi1, Gábor Juhász, Dénes Budai, Botond Penke.   

Abstract

Aggregated Abeta1-42 is hypothesized to be the central cause of Alzheimer's disease. However, early changes in synaptic activity may be detected in the disease long before a significant cell loss is manifested. Despite the fact that Abeta1-42 interference with long-term potentiation (LTP) and the field excitatory postsynaptic potential (fEPSP) is well documented, the exact mechanism of these events remains to be clarified. Here we studied the effects of iontophoretically applied Abeta1-42 on the neuronal firing evoked in vivo on the CA1 hippocampal neurons of Wistar rats by different agonists of the ionotropic glutamate receptors: N-methyl-d-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainic acid (KA). NMDA elicited firing enhanced in all of the measured cells; in contrast, the AMPA-mediated responses decreased significantly after Abeta1-42 ejection. The changes in KA-evoked responses to Abeta1-42 revealed two types of cells. In the first type, the KA-mediated firing remained at the control level, while in the second type, Abeta1-42 attenuated the KA-evoked responses. A protective pentapeptide, Leu-Pro-Tyr-Phe-Asp-amide, was used to verify the specificity of these beta-amyloid-elicited effects. The pentapeptide protected against the modulatory effects of Abeta1-42 on the NMDA and AMPA responses. In conclusion, we have shown that Abeta1-42 exerts divergent effects on the activity of the ionotropic glutamate receptors in vivo. These results suggest that the LTP disruption and fEPSP attenuation seen after Abeta1-42 application are in part due to the altered function of these receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16248989     DOI: 10.1016/j.brainres.2005.09.014

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

Review 1.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

3.  Soluble oligomers of amyloid-β peptide disrupt membrane trafficking of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synapse dysfunction.

Authors:  Alfredo J Miñano-Molina; Judit España; Elsa Martín; Bruna Barneda-Zahonero; Rut Fadó; Montse Solé; Ramón Trullás; Carlos A Saura; José Rodríguez-Alvarez
Journal:  J Biol Chem       Date:  2011-06-10       Impact factor: 5.157

4.  Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression.

Authors:  Yasuteru Inoue; Mitsuharu Ueda; Teruaki Masuda; Yohei Misumi; Taro Yamashita; Yukio Ando
Journal:  Mol Neurobiol       Date:  2019-07-06       Impact factor: 5.590

5.  Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5.

Authors:  Marianne Renner; Pascale N Lacor; Pauline T Velasco; Jian Xu; Anis Contractor; William L Klein; Antoine Triller
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

6.  The role of beta-amyloid protein in synaptic function: implications for Alzheimer's disease therapy.

Authors:  F Peña; Ai Gutiérrez-Lerma; R Quiroz-Baez; C Arias
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

7.  GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo.

Authors:  Neng-Wei Hu; Igor Klyubin; Roger Anwyl; Roger Anwy; Michael J Rowan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-16       Impact factor: 11.205

8.  Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model.

Authors:  Laura E McMillan; Jon T Brown; Jeremy M Henley; Helena Cimarosti
Journal:  Neurosci Lett       Date:  2011-08-04       Impact factor: 3.046

9.  Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus.

Authors:  Tahir Ali; Gwang Ho Yoon; Shahid Ali Shah; Hae Young Lee; Myeong Ok Kim
Journal:  Sci Rep       Date:  2015-06-29       Impact factor: 4.379

Review 10.  Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.

Authors:  Chris G Parsons; Wojciech Danysz; Andrzej Dekundy; Irena Pulte
Journal:  Neurotox Res       Date:  2013-05-09       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.